Join us at the 11th Global
Pharmaceutical Quality Summit 2026
Join us at the 11th Global
Pharmaceutical Quality Summit 2026
Experience Leucine AI .
Powered Pharma Operations

Transform Your Pharma Operations with AI-Powered Intelligence. Experience how Leucine's integrated platform brings together manufacturing, quality, and laboratory operations in one digital ecosystem. Schedule a personalized demo to see how our AI solutions can optimize your processes, ensure compliance, and drive operational excellence.

See How AI Transforms Your Shop Floor Operations.
Experience firsthand how Leucine's 10x MES digitalizes batch records, streamlines production, and provides real-time monitoring of your manufacturing operations. Schedule a personalized demo to discover how our AI-powered platform can enhance your productivity while maintaining compliance.

Experience AI-Driven Quality Management in Action.
See how Leucine's 10x QMS automates compliance workflows, streamlines change control, and ensures regulatory adherence. Schedule a demo to learn how our AI-powered platform can help you manage quality processes more efficiently while reducing compliance risks.

Discover Smart Laboratory Operations Management.
Watch how Leucine's 10x LES orchestrates your lab operations, automates documentation, and ensures data integrity. Schedule a demo to see how our AI-powered platform can accelerate your testing processes while maintaining audit-readiness.

Optimize your manufacturing processes with paperless operations
Strengthen quality management and regulatory compliance
Accelerate laboratory operations and testing workflows

Connect with a Leucine Expert

Schedule a 30-Minute Product Demo with Expert Q&A

Sub System /
Sample Testing

Analytics Overview

78
Form 483s Issued
13
483s converted to WL
102
Total Observation
Form 483s Issued
+74 from last period

Analytics Overview

Form 483 Conversion Rate by Year
Form 483s Issued (Yearly)

Recent Form 483s & Warning Letters

View all 483’s
Issue Date
Facility Name
Product Type
Form 483
Converted
Warning Letter
06 Feb 2026
Eugia Pharma Specialities Limited
Drugs
19 Dec 2025
JKR Pharmacy Ventures, LLC dba Doc Lane's Veterinary Pharmacy
Drugs
21 Nov 2025
Lupin Limited
Drugs
21 Nov 2025
Pharmathen International S.A.
Drugs
21 Nov 2025
Shilpa Medicare Limited
Drugs

Top Investigators

Investigator Name
Form 483 Count
Warning Letter Count
Kiya Hamilton
13
0
LaiMing Lee
13
0
David Carlson
13
0
Christy Osgood
13
0
Li Wang
13
0
TITLE/ COMPANY Issue Date Status Details
Established laboratory control mechanisms are not followed
Eugia Pharma Specialities Limited
06 Feb 2026 Normal Justification: A direct issue with Sample Testing as the OOS results arise from testing practices, necessitating revised procedural adherence.
Excerpt: Approximately 35% of the invalidations of OOS results were recorded...57% attributed to analyst error and 18% to equipment errors.
View Details
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to final specifications
Eugia Pharma Specialities Limited
06 Feb 2026 Normal Justification: The observation highlights deficiencies in testing procedures that directly align with Sample Testing, affecting product quality.
Excerpt: A demonstration of the firm’s destructive testing method was performed, and the visual operator was observed manually tapping the contents.
View Details
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance
JKR Pharmacy Ventures, LLC dba Doc Lane's Veterinary Pharmacy
19 Dec 2025 Normal Justification: Sample Testing is crucial for verifying drug conformance to identity and strength; its absence directly impacts release procedures.
Excerpt: Your firm does not conduct routine testing for potency (assay) for all drug products produced by your firm.
View Details
Laboratory controls do not include the establishment of scientifically sound and appropriate specifications and test procedures
Shilpa Medicare Limited
21 Nov 2025 Normal Justification: Sample invalidity due to small sample sizes points directly to issues within "Sample Testing" procedures.
Excerpt: The sample size of (b) (4) ml for (b)(4) (b)(4) used during microbial examination... is not appropriate to derive a statistically valid number of colonies.
View Details
Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures
Pharmathen International S.A.
21 Nov 2025 Normal Justification: The observation details issues directly linked to sample testing practices, crucial for drug safety.
Excerpt: Bubbles were observed between the (b)(4) and the media for (b)(4) samples.
View Details

Prepare Better for FDA Audits with FDA Tracker

Get Real-time Insights: FDA 483s & Warning letters.
Uncover Trends: FDA Investigator profiles & Observations.
Stay Compliant: Manage risks proactively.

Sample Testing

Explore essential insights on batch release processes to enhance compliance and quality. Dive into our article for practical guidance and best practices.

Sample Testing

Overview

78
Form 483s Issued
13
483s converted to WL
102
Total Observation
Form 483s Issued
+74 from last period

Recent Form 483s & Warning Letters

Issue Date
Facility Name
Product Type
Form 483
Converted
Warning Letter
06 Feb 2026
Eugia Pharma Specialities Limited
Drugs
19 Dec 2025
JKR Pharmacy Ventures, LLC dba Doc Lane's Veterinary Pharmacy
Drugs
21 Nov 2025
Lupin Limited
Drugs
21 Nov 2025
Pharmathen International S.A.
Drugs
21 Nov 2025
Shilpa Medicare Limited
Drugs

Top FDA Investigators

Investigator Name
Form 483 Count
Warning Letter Count
Kiya Hamilton
13
0
LaiMing Lee
13
0
David Carlson
13
0
Christy Osgood
13
0
Li Wang
13
0

Key Observations

TITLE/ COMPANY Issue Date Status Details
Established laboratory control mechanisms are not followed
Eugia Pharma Specialities Limited
06 Feb 2026 Normal Justification: A direct issue with Sample Testing as the OOS results arise from testing practices, necessitating revised procedural adherence.
Excerpt: Approximately 35% of the invalidations of OOS results were recorded...57% attributed to analyst error and 18% to equipment errors.
View Details
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to final specifications
Eugia Pharma Specialities Limited
06 Feb 2026 Normal Justification: The observation highlights deficiencies in testing procedures that directly align with Sample Testing, affecting product quality.
Excerpt: A demonstration of the firm’s destructive testing method was performed, and the visual operator was observed manually tapping the contents.
View Details
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance
JKR Pharmacy Ventures, LLC dba Doc Lane's Veterinary Pharmacy
19 Dec 2025 Normal Justification: Sample Testing is crucial for verifying drug conformance to identity and strength; its absence directly impacts release procedures.
Excerpt: Your firm does not conduct routine testing for potency (assay) for all drug products produced by your firm.
View Details
Laboratory controls do not include the establishment of scientifically sound and appropriate specifications and test procedures
Shilpa Medicare Limited
21 Nov 2025 Normal Justification: Sample invalidity due to small sample sizes points directly to issues within "Sample Testing" procedures.
Excerpt: The sample size of (b) (4) ml for (b)(4) (b)(4) used during microbial examination... is not appropriate to derive a statistically valid number of colonies.
View Details
Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures
Pharmathen International S.A.
21 Nov 2025 Normal Justification: The observation details issues directly linked to sample testing practices, crucial for drug safety.
Excerpt: Bubbles were observed between the (b)(4) and the media for (b)(4) samples.
View Details

Frequently Asked Questions

Heading 1

Heading 2

Heading 3

Heading 4

Heading 5
Heading 6

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

Block quote

Ordered list

  1. Item 1
  2. Item 2
  3. Item 3

Unordered list

  • Item A
  • Item B
  • Item C

Text link

Bold text

Emphasis

Superscript

Subscript

Experience Leucine AI Powered pharma manufacturing
300+ pharma facilities worldwide use Leucine to stay compliant. Talk to one of our expert consultants at Leucine to learn how.
Related Resources

View and learn more about FDA Inspections
with our comprehensive list of resources